BioSpace Feature: Advancing Cyclic Peptides from Discovery to Scalable Manufacturing

News

}

Home / News / Company News / Company News detail

Time: 2026-09-16

Source: Viva Biotech

[Abstract]:In a recent BioSpace feature, Viva Biotech experts discuss cyclic peptide discovery, development and manufacturing.

Cyclic peptides are gaining momentum as a therapeutic modality, with the potential to combine the oral convenience of small molecules with antibody-like selectivity. Their development, however, still requires careful optimization of bioavailability, PK, synthesis reproducibility, impurity control and scale-up.

In a recent BioSpace feature, Viva Biotech experts Dr. Susan Chen, Chief Technology Officer, and Dr. Yue Qian, VP & Head of MARS Division, discuss how AI-enabled peptide design, ADME/PK modeling and hybrid SPPS/LPPS synthesis strategies can support peptide discovery and development. Viva's hybrid synthesis approach has also been applied to kilogram-scale GLP-1 analogue preparation at ≥99% purity.

The article also explores the importance of connecting discovery with downstream development and manufacturing early, highlighting Viva Biotech's integrated capabilities across AI-enabled design, peptide synthesis, process development, analytics, formulation and manufacturing.

Read the full BioSpace article:
https://www.biospace.com/drug-development/cyclic-peptides-open-new-drug-frontiers-if-manufacturing-can-keep-up

Previous Page：None... Next Page：Unlocking TPD Modality Bottlenecks | One-Stop CRO Platform Empowers New-Drug Discovery of PROTACs, Molecular Glues and RIPTACs

Back

Media contact: vivapr@vivabiotech.com